Bladder Cancer

As leaders in the development of the most sophisticated treatments for people with bladder cancer, we have one of the largest programs in the United States. A team of urologic surgeons, medical oncologists, imaging specialists, and urologic pathologists collaborates to diagnose and treat people with bladder cancer.

Our research studies give you access to the newest approaches to care, including the latest diagnostic imaging techniques, such as PET/MRI scans, and advanced treatments, including immunotherapy, robotic-assisted surgery, and blue light cystoscopy to detect and remove early stage bladder cancer.

Clinical Trials and Research Studies

Phase 1

Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors

Phase 1

A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Phase 1/2

A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Phase 1

A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Ad